Cryoport, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $11.50.

Several research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a research report on Wednesday, March 5th. Guggenheim assumed coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock.

Cryoport Stock Up 5.9 %

Shares of NASDAQ CYRX opened at $7.04 on Thursday. The firm’s 50-day simple moving average is $7.17 and its 200 day simple moving average is $7.52. The company has a market cap of $347.99 million, a price-to-earnings ratio of -2.08 and a beta of 1.67. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport has a 12-month low of $4.58 and a 12-month high of $20.11.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the company earned ($0.29) EPS. On average, research analysts expect that Cryoport will post -0.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after acquiring an additional 2,120 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Cryoport in the 4th quarter valued at approximately $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport in the 4th quarter valued at approximately $64,000. Quarry LP acquired a new stake in shares of Cryoport in the 4th quarter valued at approximately $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport in the 3rd quarter valued at approximately $82,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.